June 13th 2025
Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.
Radiation Oncology’s Role in the Next Chapter of Payment Reform
Amy Ellis: There Was a Big Shift to Telemedicine in Cancer Care Delivery